摘要
目的：研究Ｆｌｔ３基因在不同类型、亚型白血病中ｍＲＮＡ表达、分布情况，以期阐明Ｆｌｔ３基因表达与疾病发生、发展的关系，探索Ｆｌｔ３基因作为白血病转归及预后指标的意义。方法：应用血细胞Ｐｅｒｃｏｌｌ不连续密度梯度分离法分离出外周血中原始细胞，采用逆转录－聚合酶链反应（ＲＴ－ＰＣＲ），检测Ｆｌｔ３基因在１０９例恶性血液病患者外周血中表达。结果：初治 ＡＭＬ（急性髓细胞性白血病）中 Ｆｌｔ３基因 ｍＲＮＡ表达为 ９１.４％ ； ＡＬＬ（急性淋巴细胞性白血病）中表达率亦较高，为 ８２.３％；在急性白血病的 ＣＲ（完全缓解）病例中原 Ｆｌｔ３阳性表达可转为阴性；而 ＮＲ（未缓解）的患者则持续为阳性表达。ＣＭＬ（慢性髓细胞性白血病）中阳性表达为３３．９％，仅见于急变期及加速期，在慢性阶段则无表达。６例ＣＬＬ（慢性淋巴细胞性白血病）中的４例、４例ＭＤＳ（骨髓增生异常综合征）中的２例表达Ｆｌｔ３。结论：Ｆｌｔ３基因有望在白血病诊治过程中成为标志性基因。
Objectives: To investigate the expression of Flt3 gene in leukemia and indicate the relation between the expression of Flt3 gene and the occurrence or the development of the disease. Methods: The separation method of the Percoll discontinuous density gradient was applied to isolate the blast cells in peripheral blood. RT-PCR was used to detect the mRNA expressions of Fit3 in blast cells of peripheral blood from 109 malignant patients. Results: The high level of the Fit3 mRNA in primary AML blasts from 35 patients peripheral blood was 91.4% with no apparent predominaoce of any of the M1-M6 subtypes, Flt3 mRNA in ALL also was found at high level in 82.4%. When the patients were in complete remission(CR), their expression could be changed from positive to negative. But the positive rates was continual if the leukemia cases were non-remission (NH). The positive rate in CML sample was 33.9% which was attained merely to accelerated phase and blast crisis, whereas it was not found in chronic phase. Flt3 mRNA was detected in 4/6 cases of CLL and 2/4 cases Of MDS. Conclusion: Flt3 gene will hopefully become a symbolic gene during the course of diagnosis and treatment in leukemias.
出处
《癌症》
SCIE
CAS
CSCD
北大核心
2000年第6期589-593,共5页
Chinese Journal of Cancer
